Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Revenue projections:

Revenue projections for TORNTPHARM
Revenue projections for TORNTPHARM

TORNTPHARM is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 0.00000
forwardPE 39.36155
debtToEquity 42.81000
earningsGrowth 0.19800
revenueGrowth 0.11200
grossMargins 0.75869
operatingMargins 0.26149
trailingEps 59.22000
forwardEps 0.00000

TORNTPHARM's positive earnings and revenue growth suggest that the company is poised for business expansion. This financial strength indicates that TORNTPHARM is expected to continue growing, with rising profits and sales contributing to its long-term success.
Torrent Pharmaceuticals Limited's positive gross and operating margins indicate the company's ability to operate profitably. These margins reflect strong financial management, with efficient cost control contributing to sustained profitability and a solid financial outlook.

Price projections:

Price projections for TORNTPHARM
Price projections for TORNTPHARM

Over time, price projections for TORNTPHARM have risen steadily, pointing to growing optimism among analysts about the company's future. This upward trend suggests a positive outlook for TORNTPHARM's continued growth.

Insider Transactions:

Insider Transactions for TORNTPHARM
Insider Transactions for TORNTPHARM


TORNTPHARM saw 1 transactions to buy shares, with a market price of 3224.449951171875.During the review period, no buy transactions were executed.TORNTPHARM's current price levels have seen more selling than buying, which may indicate potential for further decline. If this trend continues, the stock could experience additional price drops, as selling pressure grows.

Recommendation changes over time:

Recommendations trend for TORNTPHARM
Recommendations trend for TORNTPHARM


The recent buy bias from analysts suggests TORNTPHARM is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, TORNTPHARM appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.